Multi-cancer Early DetectionNCT06870916
Supporting Informed Decision Making About Multi-cancer Early Detection Testing
An observational study of Multi-cancer Early Detection, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To develop a new participant educational aid that can be used by participants to support informed decision-making about Multi-Cancer Early Detection (MCED) tests, which are new blood-based screening tests. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Multi-cancer Early Detection
- What is being tested?
- Multi-cancer Early Detection
- How many people
- 150 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Mar 2025to 1 Jan 2027
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Recruitment and eligibility will be assessed by CCETR.CCETR staff will help distribute recruitment flyers, assess subject eligibility, and refer eligible subjects to the research team (Appendix B, C \& I).
Who cannot join
- History of cancer other than basil cell and squamous cell skin cancer, per self-report.
Trial locations and contacts
1 site in 1 country.
About this study
To develop a new participant educational aid that can be used by participants to support informed decision-making about Multi-Cancer Early Detection (MCED) tests, which are new blood-based screening tests.
Read the detailed description
To develop a prototype participant educational aid that can be used by participants to support informed decision making about MCED testing. The aims of the pilot project include the following:
- Conduct focus groups to explore preferences and concerns about MCED testing among adults of screening age.
- Based on salient themes from focus group discussion, develop and administer surveys to explore preferences and concerns about MCED testing among adults of screening age.
- Using findings from the focus groups and surveys, develop prototype patient educational aids about MCED testing following a user-centered design strategy.
- Conditions
- Multi-cancer Early Detection
- Being tested
- Multi-cancer Early Detection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multi-cancer Early DetectionOther
Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.
| Study group | Role | What they receive |
|---|---|---|
| Multi-cancer Early Detection | Participants will participate in a focus group discussion asking about participants knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits. Receives: Other: Multi-cancer Early Detection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Adverse Events (AEs)
Measured: Through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2025
- Study start7 Mar 2025
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jan 2027 (estimated)
Why it stopped: PI Request
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multi-cancer Early DetectionStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Robert Volk, PHD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06870916
- Sponsor's protocol ID
- 2024-1925
- Other IDs
- NCI-2025-01726
- Status last verified
- Sep 2026
- First submitted
- 4 Mar 2025
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supporting Informed Decision Making About Multi-cancer Early Detection Testing
- ClinicalTrials.gov ID
- NCT06870916
- Acronym / sponsor ID
- 2024-1925
- Conditions
- Multi-cancer Early Detection
- Study type
- Observational
- Recruitment status
- SuspendedReason stopped: PI Request
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 7 Mar 2025 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 11 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To develop a new participant educational aid that can be used by participants to support informed decision-making about Multi-Cancer Early Detection (MCED) tests, which are new blood-based screening tests.
Detailed description
To develop a prototype participant educational aid that can be used by participants to support informed decision making about MCED testing. The aims of the pilot project include the following:
- Conduct focus groups to explore preferences and concerns about MCED testing among adults of screening age.
- Based on salient themes from focus group discussion, develop and administer surveys to explore preferences and concerns about MCED testing among adults of screening age.
- Using findings from the focus groups and surveys, develop prototype patient educational aids about MCED testing following a user-centered design strategy.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multi-cancer Early Detection | – | Other: Multi-cancer Early DetectionParticipants will participate in a focus group discussion asking about participants knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (1 listed)
- Recruitment and eligibility will be assessed by CCETR.CCETR staff will help distribute recruitment flyers, assess subject eligibility, and refer eligible subjects to the research team (Appendix B, C \& I).
Key exclusion criteria (1 listed)
- History of cancer other than basil cell and squamous cell skin cancer, per self-report.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multi-cancer Early DetectionParticipants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits. | Other | Multi-cancer Early Detection |
Primary outcome
Safety and Adverse Events (AEs)
Time frame: Through study completion; an average of 1 year.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Multi-cancer Early Detection
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingObservational study
A Study Evaluating the Performance of Using AI Software and Chest X-rays to Screen for Osteoporosis as Compared to Standard DXA Scans in Patients 50 Years and Older
Osteoporosis, Osteopenia
Recruiting
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer
Not yet recruiting
Biomarker Investigation for Early Gastric Cancer Detection
Gastro Oesophageal Cancer
Not yet recruitingObservational study
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
Pulmonary Nodules, Early Detection of Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Volk, PHD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multi-cancer Early Detection, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Adverse Events (AEs) (time frame: Through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.